Thaddäus Strzalkowski on Muck Rack

Thaddäus Strzalkowski

As seen in: Nature
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Thaddäus

Contact Thaddäus, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Ablation of prostaglandin E2 signalling through dual receptor knockout in CAR T cells enhances therapeutic efficacy in solid tumours - Nature Biomedical Engineering

|
By Janina Dörr, Lisa Gregor, Sebastian Lacher, Arman Oner, Yi Sun, Ignazio Piseddu, Luisa Fertig, Stefanie Lesch, Stefanos Michaelides, Matthias Seifert, Adrian Gottschlich, Daria Briukhovetska, Donjete Simnica, Kathrin Gabriel, Sonia Cohen, Genevieve M. Boland, David Andreu-Sanz, Emanuele Carlini, Sophia Stock, Anne V. Holtermann, Philipp Müller , Thaddäus Strzalkowski, Marcel P. Trefny, Stefan Endres, Russell Jenkins, Jan P. Böttcher, Sebastian Kobold, Sebastijan Spajic, Natasha Samson, Lina Majed, Viktoria Hartmann
| Nature
Abstract The efficacy of chimeric antigen receptor (CAR) T cell therapy in solid cancers is limited by immunosuppression in the tumour microenvironment (TME). Prostaglandin E2 (PGE2) is a key factor locally inhibiting T cell function. We hypothesized that targeted ablation of PGE2 signalling in CAR T cells may enhance their activity in PGE2-rich solid tumours. Here we generate knockout CAR T cells double deficient for the PGE2 receptors EP2 and EP4 (EP2−/−EP4−/−) by CRISPR–Cas9 engineering.
Open in Who Shared Issue with article?

Single-cell transcriptomic atlas-guided development of CAR-T cells for the treatment of acute myeloid leukemia - Nature Biotechnology

|
By Adrian Gottschlich, Moritz Thomas, Ruth Grünmeier, Daria Briukhovetska, Binje Vick, Florian Markl, Sophia Stock, Matthias Seifert, Bruno L. Cadilha, Christian Kellner, Eduardo Beltrán, Tobias Herold, Dominik Paquet, Louisa von Baumgarten, Carsten Marr, Stefanie Lesch, Veronika Igl, Sertac Dede, Thaddäus Strzalkowski, Theo Lorenzini, Franziska Modemann
| Nature
Abstract Chimeric antigen receptor T cells (CAR-T cells) have emerged as a powerful treatment option for individuals with B cell malignancies but have yet to achieve success in treating acute myeloid leukemia (AML) due to a lack of safe targets.
Open in Who Shared Issue with article?
See all 2 articles

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Get in touch with Thaddäus

Contact Thaddäus, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified